Prosight Management, LP Neurocrine Biosciences Inc Transaction History
Prosight Management, LP
- $320 Million
- Q2 2024
A detailed history of Prosight Management, LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Prosight Management, LP holds 27,000 shares of NBIX stock, worth $3.11 Million. This represents 1.16% of its overall portfolio holdings.
Number of Shares
27,000
Previous 30,500
11.48%
Holding current value
$3.11 Million
Previous $4.21 Million
11.63%
% of portfolio
1.16%
Previous 1.21%
Shares
6 transactions
Others Institutions Holding NBIX
# of Institutions
641Shares Held
95.3MCall Options Held
661KPut Options Held
227K-
Black Rock Inc. New York, NY14.2MShares$1.63 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.16 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$531 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$284 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$272 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...